Abstract
BackgroundPlasma d-dimer levels have been associated with the status of tumor progression or oncological outcomes in cancer. Although there are many evidences suggesting the involvement of procoagulant trend in musculoskeletal sarcoma, no clinical data on d-dimer levels and oncological outcome of musculoskeletal sarcoma has been reported.MethodsIn this study, we included a total of 85 patients who were diagnosed with musculoskeletal sarcoma and treated at our institute. Plasma d-dimer levels were determined before performing any clinical intervention, including open biopsy, chemotherapy, radiotherapy or tumor resection. We evaluated the effect of d-dimer levels and other clinicopathological factors on oncological outcomes of patients.ResultsUpregulation of plasma d-dimer levels proved to be an independent risk factor for metastasis and lethal outcome of patients with musculoskeletal sarcoma.ConclusionsUpregulation of plasma d-dimer levels were indicated poor oncological outcome in metastasis and total survival rate of musculoskeletal sarcoma patients. Hence d-dimer levels may be a helpful marker for evaluating the tumor progression status and prognosis of musculoskeletal sarcoma.
Highlights
Plasma d-dimer levels have been associated with the status of tumor progression or oncological outcomes in cancer
The risk of venous thromboembolism is higher in cancer patients than in non-cancer patients [1]
The incidence of venous thromboembolism caused by systemic activation of clotting-fibrinolytic system in musculoskeletal sarcoma patients is considerably high [2,3,4,5]
Summary
Plasma d-dimer levels have been associated with the status of tumor progression or oncological outcomes in cancer. There are many evidences suggesting the involvement of procoagulant trend in musculoskeletal sarcoma, no clinical data on d-dimer levels and oncological outcome of musculoskeletal sarcoma has been reported. Deterioration in the hemostatic status is one of the significant physiological changes induced by malignant condition. Various kinds of procoagulant factors such as malignant condition itself, chemotherapy, long rest period, pathological fracture, orthopedic surgery, and reconstruction by prosthesis or plastic surgery, have been associated with musculoskeletal sarcoma. The incidence of venous thromboembolism caused by systemic activation of clotting-fibrinolytic system in musculoskeletal sarcoma patients is considerably high [2,3,4,5]. Direct or collateral evidences suggested the involvement of procoagulant molecular mechanisms in
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
